Impaired BDNF-TrkB trafficking and signalling in Down syndrome basal forebrain neurons

Read full text
Authors: Emily Blackburn, Nicol Birsa, André T. Lopes, Elizabeth M. C. Fisher, Oscar M. Lazo, Giampietro Schiavo
Cited by: 3
References: 71

Abstract

Brain derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase B (TrkB) play crucial roles in neuronal development, synaptic transmission, and neuroplasticity. Deficits in BDNF/TrkB signalling and trafficking have been identified in several neurodegenerative diseases, including Alzheimer's disease (AD). Individuals with Down syndrome (DS) are at an increased risk of developing AD compared to the general population. Basal forebrain neurons (BFNs) are among the first to degenerate in AD and DS, but the mechanisms underlying their vulnerability remain unclear. Using BFNs derived from the Dp1Tyb mouse model of DS, we investigated neurotrophic signalling and trafficking deficits in AD-DS. We found enlarged early endosomes and elevated levels of active Rab5, a GTPase critical for early endosome formation, in Dp1Tyb BFNs. These abnormalities were associated with impaired transport of internalised TrkB from axon terminals to the soma. Using microfluidic devices, we demonstrated that axonal BDNF stimulation enhanced signalling endosome dynamics in wild-type but not Dp1Tyb BFNs, which is likely due to impaired axonal ERK1/2 signalling. Our findings establish a link between Rab5 hyperactivation, endosomal dysfunction, and impaired ERK1/2 signalling, highlighting the interplay between trafficking and neurotrophic signalling, and underscore the importance of targeting endolysosomal and signalling pathways to mitigate neuronal dysfunction in AD-DS.

Fields of Study & Subjects

Down syndrome and intellectual disability research Cellular transport and secretion Alzheimer's disease research and treatments

Publication details

Journal / source
Cell Death and Disease
Publisher
Springer Science and Business Media LLC
Volume
17
Issue
1
Pages
214–214
Publication date
11 February 2026
Language
EN